

**REMARKS**

In response to the Office Action/Restriction Requirement, mailed October 20, 2005), for which a two month extension of time petition and fee submission/authorization is filed herewith, extending the time for response from November 20, 2004 to January 20, 2005. As presented on pages 2-6 of this paper, original claims 15-17, 25-36, 39-44 and 52-54 remain in this application, claims 1-5, 7 and 50 have been amended to more particularly recite the invention, to correct typographical errors, and to address the species election required by the Examiner; and claims 6, 8-14, 18-24, 37-38, 45-49, 51 and 55 have been canceled, without prejudice to filing divisional or continuation applications including one or more of these claims as filed or in amended form, or additional claims directed to these or additional inventions.

The Examiner has issued a Restriction Requirement Office Action, presenting on pages 2-11 of the Action that the filed claims constitute 6 distinct inventions, apparently as the following, which have been clarified according to the apparent position of the Examiner, as respectively:

- (1) At least one human Ig derived protein specific for a RELP protein of SEQ ID NO:2 or a portion thereof, formulations, articles of manufacture, devices and compositions: claims 1-5, 7, 15-17, 25-36, 39-44, 50 and 52-55;
- (2) DNA, vectors, hosts cells and methods for a human Ig derived protein specific for a RELP protein of SEQ ID NO:2 or a portion thereof: claims 6, 8-13, and 55.
- (3) In vitro or in vivo method of producing for a human Ig derived protein specific for a RELP protein of SEQ ID NO:2 or a portion thereof: claims 14, 45-48 and 55;
- (4) Methods of treating a malignant disease or condition using a human Ig derived protein specific for a RELP protein of SEQ ID NO:2 or a portion thereof: claims 18-24, 37-38, 51 and 55;
- (5) Transgenic animals expressing a human Ig derived protein specific for a RELP protein of SEQ ID NO:2 or a portion thereof: claims 49 and 55.


Appl No. 10/099,791  
Amdt. Dated January 20, 2005  
Reply to Office Communication of October 20, 2004

- (6) Transgenic plants expressing a human Ig derived protein specific for a RELP protein of SEQ ID NO:2 or a portion thereof: claims 49 and 55.

Applicants acknowledge this part of the restriction requirement without traverse and elected group (I) directed to at least one human Ig derived protein specific for a RELP protein of SEQ ID NO:2 or a portion thereof, formulations, articles of manufacture, devices and compositions: claims 1-5, 7, 15-17, 25-36, 39-44, 50 and 52-55. Applicants have amended and canceled the claims as presented above to address the restriction requirement and species election, with the proviso that Applicant reserves the right to file or add additional claims and species according to the results of the search and examination by the Examiner.

Applicant respectfully requests that a timely Notice of Allowance be issued in this case of the now pending and amended claims.

Respectfully submitted,

By:   
Guy Kevin Townsend  
Reg. No. 34,033

Johnson & Johnson  
One Johnson & Johnson Plaza  
New Brunswick, NJ 08933-7003  
(732) 524-2517  
Dated: January 20, 2005